全文获取类型
收费全文 | 30841篇 |
免费 | 2873篇 |
国内免费 | 1536篇 |
专业分类
耳鼻咽喉 | 173篇 |
儿科学 | 527篇 |
妇产科学 | 450篇 |
基础医学 | 3788篇 |
口腔科学 | 473篇 |
临床医学 | 4485篇 |
内科学 | 4835篇 |
皮肤病学 | 278篇 |
神经病学 | 2181篇 |
特种医学 | 1094篇 |
外国民族医学 | 20篇 |
外科学 | 2942篇 |
综合类 | 3645篇 |
现状与发展 | 5篇 |
一般理论 | 14篇 |
预防医学 | 2550篇 |
眼科学 | 1061篇 |
药学 | 3028篇 |
33篇 | |
中国医学 | 1405篇 |
肿瘤学 | 2263篇 |
出版年
2024年 | 77篇 |
2023年 | 377篇 |
2022年 | 1077篇 |
2021年 | 1436篇 |
2020年 | 1067篇 |
2019年 | 996篇 |
2018年 | 1108篇 |
2017年 | 881篇 |
2016年 | 866篇 |
2015年 | 1160篇 |
2014年 | 1590篇 |
2013年 | 1525篇 |
2012年 | 2168篇 |
2011年 | 2285篇 |
2010年 | 1397篇 |
2009年 | 1208篇 |
2008年 | 1650篇 |
2007年 | 1674篇 |
2006年 | 1730篇 |
2005年 | 1620篇 |
2004年 | 1229篇 |
2003年 | 1219篇 |
2002年 | 1073篇 |
2001年 | 524篇 |
2000年 | 652篇 |
1999年 | 667篇 |
1998年 | 446篇 |
1997年 | 453篇 |
1996年 | 333篇 |
1995年 | 307篇 |
1994年 | 267篇 |
1993年 | 178篇 |
1992年 | 243篇 |
1991年 | 175篇 |
1990年 | 170篇 |
1989年 | 140篇 |
1988年 | 143篇 |
1987年 | 129篇 |
1986年 | 115篇 |
1985年 | 107篇 |
1984年 | 70篇 |
1983年 | 65篇 |
1982年 | 59篇 |
1981年 | 45篇 |
1980年 | 33篇 |
1979年 | 53篇 |
1974年 | 47篇 |
1973年 | 34篇 |
1967年 | 34篇 |
1966年 | 31篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Zeyu Li Erwei Hao Rui Cao Si Lin Linghui Zou Tianyan Huang Zhengcai Du Xiaotao Hou Jiagang Deng 《中草药(英文版)》2022,14(4):479-493
Zedoary tumeric (Curcumae Rhizoma, Ezhu in Chinese) has a long history of application and has great potential in the treatment of liver cancer. The anti liver cancer effect of zedoary tumeric depends on the combined action of multiple pharmacodynamic substances. In order to clarify the specific mechanism of zedoary tumeric against liver cancer, this paper first analyzes the mechanism of its single pharmacodynamic substance against liver cancer, and then verifies the joint anti liver cancer mechanism of its "pharmacodynamic group". By searching the research on the anti hepatoma effect of active components of zedoary tumeric in recent years, we found that pharmacodynamic substances, including curcumol, zedoarondiol, curcumenol, curzerenone, curdione, curcumin, germacrone, β-elemene, can act on multi-target and multi-channel to play an anti hepatoma role. For example, curcumin can regulate miR, GLO1, CD133, VEGF, YAP, LIN28B, GPR81, HCAR-1, P53 and PI3K/Akt/mTOR, HSP70/TLR4 and NF-κB. Wnt/TGF/EMT, Nrf2/Keap1, JAK/STAT and other pathways play an anti hepatoma role. Network pharmacological analysis showed that the core targets of the "pharmacodynamic group" for anti-life cancer are AKT1, EGFR, MAPK8, etc, and the core pathways are neuroactive live receiver interaction, nitrogen metabolism, HIF-1 signaling pathway, etc. At the same time, by comparing and analyzing the relationship between the specific mechanisms of pharmacodynamic substance and "pharmacodynamic group", it is found that they have great reference significance in target, pathway, biological function, determination of core pharmacodynamic components, formation of core target protein interaction, in-depth research of single pharmacodynamic substance, increasing curative effect and so on. By analyzing the internal mechanism of zedoary tumeric pharmacodynamic substance and "pharmacodynamic group" in the treatment of liver cancer, this paper intends to provide some ideas and references for the deeper pharmacological research of zedoary tumeric and the relationship between pharmacodynamic substance and "pharmacodynamic group". 相似文献
2.
3.
儿童晕厥临床诊治研究的发展与未来 总被引:1,自引:0,他引:1
儿童晕厥在临床常见,严重影响儿童的身心健康.儿童晕厥诊断关键技术的建立、诊断程序及个体化治疗新策略的提出,显著提高了儿童晕厥的诊治水平.基于研究成果,我国先后制定了多部儿童晕厥诊治指南与专家共识,并在国际期刊颁布了儿童和青少年晕厥指南,充分发挥了中国在国际儿童晕厥诊治领域的引领作用.今后尚需进一步开展儿童晕厥的流行病学研究,优化儿童晕厥预警体系以及干预与预防新策略,进一步推进儿童晕厥事业的发展. 相似文献
4.
5.
Sundaram Kavin Piuzzi Nicolas S. Patterson Brendan M. Stearns Kim L. Krebs Viktor E. Mont Michael A. 《European journal of orthopaedic surgery & traumatology : orthopedie traumatologie》2020,30(3):447-453
European Journal of Orthopaedic Surgery & Traumatology - The goals of this study were to compare patient satisfaction and wound-related complications in patients receiving 2-octyl cyanoacrylate... 相似文献
6.
7.
8.
Conan MacDougall Theora Canonica Chris Keh Binh An P. Phan Janice Louie 《Pharmacotherapy》2022,42(4):343-361
Rifamycins (rifampin, rifabutin, and rifapentine) play an essential role in the treatment of mycobacterial and some nonmycobacterial infections. They also induce the activity of various drug transporting and metabolizing enzymes, which can impact the concentrations and efficacy of substrates. Many anticoagulant and antiplatelet (AC/AP) agents are substrates of these enzymes and have narrow therapeutic indices, leading to risks of thrombosis or bleeding when coadministered with rifamycins. The objective of this systematic review was to evaluate the effects on AC/AP pharmacokinetics, laboratory markers, and clinical safety and efficacy of combined use with rifamycins. A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidance was performed. The PubMed, Embase, and Web of Science databases were queried for English-language reports on combination use of rifamycins and AC/AP agents from database inception through August 2021. The 29 studies identified examined warfarin (n = 17), direct oral anticoagulants (DOACs) (n = 8), and antiplatelet agents (n = 4) combined with rifampin (n = 28) or rifabutin (n = 1). Eleven studies were case reports or small case series; 14 reported on pharmacokinetic or laboratory markers in healthy volunteers. Rifampin-warfarin combinations led to reductions in warfarin area under the curve (AUC) of 15%–74%, with variability by warfarin isomer and study. Warfarin dose increases of up to 3–5 times prerifampin doses were required to maintain coagulation parameters in the therapeutic range. DOAC AUCs were decreased by 20%–67%, with variability by individual agent and with rifampin versus rifabutin. The active metabolite of clopidogrel increased substantially with rifampin coadministration, whereas prasugrel was largely unaffected and ticagrelor saw decreases. Our review suggests most combinations of AC/AP agents and rifampin are problematic. Further studies are required to determine whether rifabutin or rifapentine could be safe alternatives for coadministration with AC/AP drugs. 相似文献
9.
10.